According to a post on the FDA’s website, Kymera Therapeutics’ Selective heterobifunctional small molecule degrader of mouse double minute 2, MDM2, was granted orphan designation in treatment of acute myeloid leukemia.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KYMR:
- Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
- Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
- Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
- Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
- Kymera Therapeutics to Participate in Upcoming June Investor Conference